{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:54Z","timestamp":1793666754083,"version":"4.5.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The purpose of this review is to summarize the current knowledge concerning the mechanisms of action of Abatacept in patients with rheumatoid arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Abatacept (CTLA-4Ig) represents a soluble, recombinant, fully humanized fusion protein, comprising the extracellular domain of CTLA-4 and the Fc portion of IgG1. Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), thereby blocking interaction with CD28 on T cells. In humans, Abatacept treatment was shown to be effective in patients with various autoinflammatory diseases including rheumatoid arthritis. Although the prevention of T-cell activation by interfering with signaling via CD28 still represents the main mechanism of action Abatacept acts on additional cell populations including regulatory T cells (Treg), monocytes\/macrophages, osteoclasts, and B cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Effects of Abatacept on other cell populations besides T cells have to be taken into account and might represent a valuable contribution to the therapeutic success.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000491","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T18:36:13Z","timestamp":1517769373000},"page":"295-300","source":"Crossref","is-referenced-by-count":67,"title":["How does abatacept really work in rheumatoid arthritis?"],"prefix":"10.1097","volume":"30","author":[{"given":"Michael","family":"Bonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Scheinecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1975.3","article-title":"A new analysis of allogeneic interactions","volume":"53","author":"Lafferty","year":"1975","journal-title":"Aust J Exp Biol Med Sci"},{"issue":"(suppl 1)","key":"R2-20230828","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar2414","article-title":"T-cell co-stimulatory pathways in autoimmunity","volume":"10","author":"Goronzy","year":"2008","journal-title":"Arthritis Res Ther BioMed Central;"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.174.1.180","article-title":"CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway","volume":"174","author":"Wu","year":"2005","journal-title":"J Immunol"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.4049\/jimmunol.149.5.1556","article-title":"The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells","volume":"149","author":"Norton","year":"1992","journal-title":"J Immunol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.coi.2004.03.006","article-title":"The regulation of lymphocyte activation by inhibitory receptors","volume":"16","author":"Leibson","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.4049\/jimmunol.165.9.5041","article-title":"Blockade of costimulation through B7\/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance","volume":"165","author":"Silver","year":"2000","journal-title":"J Immunol"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1034\/j.1600-065X.2003.00009.x","article-title":"T cell anergy and costimulation","volume":"192","author":"Appleman","year":"2003","journal-title":"Immunol Rev"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.172.1.34","article-title":"B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]","volume":"172","author":"Taylor","year":"2004","journal-title":"J Immunol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.4049\/jimmunol.162.4.2044","article-title":"Human effector memory T cells express CD86: a functional role in naive T cell priming","volume":"162","author":"Jeannin","year":"1999","journal-title":"J Immunol"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.0105-2896.2006.00419.x","article-title":"The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology","volume":"212","author":"Sansom","year":"2006","journal-title":"Immunol Rev"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/cei.12367","article-title":"Abatacept (CTLA4-Ig) improves B cell function and Treg inhibitory capacity in rheumatoid arthritis patients non responding to anti-TNF-alpha agents","volume":"177","author":"Picchianti Diamanti","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13075-017-1309-x","article-title":"Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis","volume":"19","author":"Nakachi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2172-14-34","article-title":"CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients","volume":"14","author":"Pieper","year":"2013","journal-title":"BMC Immunol"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/rheumatology\/kev403","article-title":"Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis","volume":"55","author":"Bonelli","year":"2016","journal-title":"Rheumatology"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ni846","article-title":"CTLA-4-Ig regulates tryptophan catabolism in vivo","volume":"3","author":"Grohmann","year":"2002","journal-title":"Nat Immunol"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.172.7.4100","article-title":"Ligation of B7-1\/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells","volume":"172","author":"Munn","year":"2004","journal-title":"J Immunol"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2007.08.019","article-title":"Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction","volume":"126","author":"Davis","year":"2008","journal-title":"Clinical Immunology"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.37787","article-title":"Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis","volume":"65","author":"Bonelli","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaut.2015.05.009","article-title":"Antialpha-actinin antibodies are part of the anticell membrane antibody spectrum that characterize patients with lupus nephritis","volume":"61","author":"Seret","year":"2015","journal-title":"J Autoimmun"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ki.2013.457","article-title":"B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection","volume":"85","author":"Nou\u00ebl","year":"2014","journal-title":"Kidney Int"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.4049\/jimmunol.179.8.5109","article-title":"Expression of CD80\/86 on B cells is essential for autoreactive T cell activation and the development of arthritis","volume":"179","author":"O\u2019Neill","year":"2007","journal-title":"J Immunol"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/art.1780371113","article-title":"Elevated expression of CD80\u200a(B7\/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis","volume":"37","author":"Ranheim","year":"1994","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201805000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T01:06:50Z","timestamp":1693184810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201805000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000491","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}